Post-Hoc Analysis of Potential Correlates of Protection of a Recombinant SARS-CoV-2 Spike Protein Extracellular Domain Vaccine Formulated with Advax-CpG55.2-Adjuvant.

Int J Mol Sci · 2024 · PMC11395249 · PMID 39273405

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Notably, the Phase 3 trial also confirmed a highly significant SpikoGen ® vaccine efficacy of 77.5% in preventing severe COVID-19 disease.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.